Hipertensión arterial secundaria a enfermedad de Cushing. Reporte de Caso / Hypertension secondary to Cushing´s Disease. Report of a clinical case

INTRODUCCIÓN: La Enfermedad de Cushing es una de las causas menos prevalentes de hipertensión arterial secundaria (HTA) (0,7 a 2,4 casos por millón de personas), sin embargo conlleva un aumento de la morbi-mortalidad que se relaciona con el tiempo de exposición al exceso de corticoides 6, lo cual representa un problema debido a que la inespecificidad de los síntomas y su baja prevalencia, llevan a un retraso diagnóstico de 2 a 4 años 6, generando un incremento del riesgo cardiovascular pese a una resolución completa de la enfermedad 6-9. Este artículo tiene como objetivo describir la presentación clínica de la Enfermedad de Cushing como causa de HTA secundaria. CASO CLÍNICO: Paciente femenina de 36 años con HTA de 7 años de evolución, a quien se identificó adenoma hipofisario productor de ACTH, con posterior exéresis transesfenoidal parcial, presentando enfermedad persistente, en quien se optó manejo farmacológico a base de inhibidor de la esteroidogénesis para control de la enfermedad. DISCUSIÓN: La HTA es un problema de salud pública considerado el principal factor de riesgo para discapacidad y muerte prematura 2, con las causas secundarias como responsables de gran afectación en la calidad de vida, tomando en cuenta que estas son potencialmente curables. El manejo de la enfermedad de Cushing (EC) es principalmente quirúrgico 6,13-14, pero en caso de enfermedad persistente existen alternativas para control de la enfermedad 6,15-16, siendo los fármacos inhibidores de la esteroidogénesis los más usados. CONCLUSIONES: La EC es una causa poco frecuente hipertensión arterial secundaria, pero implica un importante compromiso de la calidad de vida, al igual que otras etiologías secundarias, por lo que es fundamental tener en cuenta las características clínicas y bioquímicas que sugieran una etiología secundaria que lleven a un diagnóstico y tratamiento oportunos.

INTRODUCTION: Cushing's Disease is one of the least prevalent causes of secondary hypertension (0.7 to 2.4 cases per million people), however it entails an increase in morbidity and mortality that is related to the chronic exposure of corticosteroids 6, which represents a problem because the no specificity of the symptoms and their low prevalence lead to a diagnostic delay of 2 to 4 years 6, increasing the cardiovascular risk despite complete resolution of the disease 6 -9. The purpose of this article aims to describe the clinical presentation of Cushing Disease (CD) as a cause of secondary hypertension. CLINICAL CASE: 36-year-old female patient with hypertension of 7 years of evolution, in whom an ACTH-producing pituitary adenoma was identified, with subsequent partial transsphenoidal excision, presenting persistent disease, in whom pharmacological management based on a steroidogenesis inhibitor was chosen. for disease control. DISCUSSION: Hypertension is a public health problem, considered the main risk factor for disability and premature death 2, with secondary causes responsible for great impact on quality of life, considering that these are potentially curative. The management of CD is mainly surgical 6,13-14, but in cases of persistent disease there are alternatives to control the disease 6,15-16, with steroidogenesis inhibitor drugs being the most used. CONCLUSIONS: CD is a rare cause of secondary hypertension, but it implies a significant compromise in quality of life, like other secondary etiologies, so it is essential to consider the clinical and biochemical characteristics that suggest a secondary etiology, which can lead to timely diagnosis and treatment.

Hipercortisolismo severo e hipocalemia recurrente / Severe hypercortisolism and recurring hypocalemia

RESUMEN El síndrome de Cushing endógeno deriva de un aumento crónico, inapropiado y sostenido de glucocorticoides principalmente como respuesta al exceso en las concentraciones séricas elevadas de la hormona adrenocorticotropa (ACTH) desde un tumor adenohipofisiario, enfermedad de Cushing; o producida de forma ectópica por tumores neuroendocrinos. El Cushing suprarrenal se origina por tumores de la corteza adrenal que producen de forma autónoma cortisol y es independiente de ACTH. El curso clínico, tratamiento, pronóstico y posibles complicaciones dependen de identificar de forma correcta la lesión desencadenante; situación que en múltiples ocasiones resulta en una experiencia retadora para los clínicos. Se presenta el caso de una mujer de 62 años, ingresada por síntomas constitucionales con hipocaliemia severa de difícil corrección e hipercortisolismo severo.

ABSTRACT Endogenous Cushing syndrome derives from a chronic, inappropriate, and sustained increase in glucocorticoids, mainly in response to remarkably high serum concentrations of adrenocorticotropic hormone (ACTH) secreted from an adenohypophyseal tumor, Cushing's disease, or due to ectopic production by neuroendocrine tumors. Adrenal Cushing's disease is caused by tumors of the adrenal cortex that autonomously produce cortisol and this is independent from ACTH action. Clinical course, treatment, prognosis, and possible complications depend on correctly identifying the triggering lesion; this situation frequently becomes a challenging experience for clinicians. We present the case of a 62-year-old woman, admitted for constitutional symptoms with severe hypokalemia that was difficult to correct and severe hypercortisolism.

Remisión espontánea de acromegalia y enfermedad de Cushing en adultos mayores: casos clínicos / Spontaneous remission of acromegaly and Cushing's disease in older patients: report of two cases

Pituitary diseases such as acromegaly and Cushing's disease require surgical or medical therapy. In some functioning pituitary tumors, a spontaneous remission of hormonal hypersecretion is observed, mainly associated to apoplexy or pituitary infarction. We report the evolution of two female patients older than 70 years at the time of diagnosis, with multiple comorbidities. In case 1, acromegaly was diagnosed at 74 years of age. Sellar CT scan showed a 10-mm adenoma. During her follow-up, IGF1 levels remained normal. Nine years later, a magnetic resonance (MR) showed a 7-mm adenoma. In case 2, clinical and biochemical diagnosis of Cushing's disease was done being 71 years old. Sellar MR showed a 6-mm adenoma. Three years later, urinary cortisol normalized with no changes in adenoma at MR. Seven years later, she remains without clinical or biochemical signs of hypercortisolism. In both cases, no signs of hemorrhage were observed at MR.

Recent Progress in the Medical Therapy of Pituitary Tumors

Management of pituitary tumors is multidisciplinary, with medical therapy playing an increasingly important role. With the exception of prolactin-secreting tumors, surgery is still considered the first-line treatment for the majority of pituitary adenomas. However, medical/pharmacological therapy plays an important role in controlling hormone-producing pituitary adenomas, especially for patients with acromegaly and Cushing disease (CD). In the case of non-functioning pituitary adenomas (NFAs), pharmacological therapy plays a minor role, the main objective of which is to reduce tumor growth, but this role requires further studies. For pituitary carcinomas and atypical adenomas, medical therapy, including chemotherapy, acts as an adjuvant to surgery and radiation therapy, which is often required to control these aggressive tumors. In the last decade, knowledge about the pathophysiological mechanisms of various pituitary adenomas has increased, thus novel medical therapies that target specific pathways implicated in tumor synthesis and hormonal over secretion are now available. Advancement in patient selection and determination of prognostic factors has also helped to individualize therapy for patients with pituitary tumors. Improvements in biochemical and “tumor mass” disease control can positively affect patient quality of life, comorbidities and overall survival. In this review, the medical armamentarium for treating CD, acromegaly, prolactinomas, NFA, and carcinomas/aggressive atypical adenomas will be presented. Pharmacological therapies, including doses, mode of administration, efficacy, adverse effects, and use in special circumstances are provided. Medical therapies currently under clinical investigation are also briefly discussed.

Clinical Guidelines for the Diagnosis and Treatment of Cushing's Disease in Korea

Cushing's disease (CD) is a rare disorder characterized by the overproduction of adrenocorticotropic hormone due to a pituitary adenoma that ultimately stimulates excessive cortisol secretion from the adrenal glands. Prior to the detection of pituitary adenomas, various clinical signs of CD such as central obesity, moon face, hirsutism, and facial plethora are usually already present. Uncontrolled hypercortisolism is associated with metabolic, cardiovascular, and psychological disorders that result in increased mortality. Hence, the early detection and treatment of CD are not only important but mandatory. Because its clinical manifestations vary from patient to patient and are common in other obesity-related conditions, the precise diagnosis of CD can be problematic. Thus, the present set of guidelines was compiled by Korean experts in this field to assist clinicians with the screening, diagnoses, and treatment of patients with CD using currently available tests and treatment modalities.

Long-term follow-up on Cushing disease patient after transsphenoidal surgery

Cushing disease is caused by excessive adrenocorticotropic hormone (ACTH) production by the pituitary adenoma. Transsphenoidal surgery is its first-line treatment. The incidence of Cushing disease in children and adolescents is so rare that long-term prognoses have yet to be made in most cases. We followed-up on a 16-year-old male Cushing disease patient who presented with rapid weight gain and growth retardation. The laboratory findings showed increased 24-hour urine free cortisol and lack of overnight cortisol suppression by low-dose dexamethasone test. The serum cortisol and 24-hour urine free cortisol, by high-dose dexamethasone test, also showed a lack of suppression, and a bilateral inferior petrosal sinus sampling suggested lateralization of ACTH secretion from the right-side pituitary gland. However, after a right hemihypophysectomy by the transsphenoidal approach, the 24-hour urine free cortisol levels were persistently high. Thus the patient underwent a total hypophysectomy, since which time he has been treated with hydrocortisone, levothyroxine, recombinant human growth hormone, and testosterone enanthate. Intravenous bisphosphonate for osteoporosis had been administered for three years. At his current age of 26 years, his final height had attained the target level range; his bone mineral density was normal, and his pubic hair was Tanner stage 4. This report describes the long-term treatment course of a Cushing disease patient according to growth profile, pubertal status, and responses to hormone replacement therapy. The clinical results serve to emphasize the importance of growth optimization, puberty, and bone health in the treatment management of Cushing disease patients who have undergone transsphenoidal surgery.

Efeitos do cetoconazol e seus mecanismos de ação in vitro sobre linhagens hipofisárias tumorais imortalizadas / Effects of ketoconazole and its mechanisms of action in pituitary tumoral immortalizaded cell lines

O cetoconazol, inicialmente descrito como um agente antifúngico, revelou-se um potente inibidor da esteroidogênese adrenal, podendo, assim, ser utilizado no manejo da doença de Cushing, como terapia primária ou após insucesso cirúrgico, enquanto aguarda o efeito da radioterapia. Durante o tratamento com cetoconazol, uma redução dos níveis de cortisol é observada, usualmente não acompanhada por uma elevação do ACTH plasmático, como poderia ser esperada. Este fenômeno paradoxal, caracterizado pela redução do cortisol com níveis de ACTH inadequadamente normais ou não elevados, pode estar relacionado a uma ação adicional do cetoconazol nas células hipofisárias produtoras de ACTH. Para se testar essa hipótese, alguns estudos in vitro realizados na década de 80, avaliando a secreção de ACTH na vigência do cetoconazol, sugeriram a sua ação em células adenohipofisárias. Em adição, foi evidenciado que o cetoconazol ativou vias de apoptose em linhagens tumorais não hipofisárias. O presente estudo tem como objetivo avaliar o efeito in vitro do cetoconazol na viabilidade celular e na expressão de genes envolvidos na apoptose e replicação do DNA em linhagens tumorais hipofisárias imortalizadas corticotróficas (AtT-20), gonadotróficas (alfaT3.1), mamossomatotróficas (GH3) e mamotróficas (MMQ), utilizando-se a técnica de RT-qPCR. Os resultados mostraram que, na presença do cetoconazol, ocorreu uma redução da viabilidade celular nas linhagens hipofisárias, de forma concentração-dependente, às custas do estímulo da via extrínseca e intrínseca da apoptose, com aumento da expressão dos receptores de morte celular (ex.: Fas, TNFR) e/ou caspases (ex.: -2, -3, -6 ,-7 ,-9). Estes resultados foram associados a um aumento da expressão gênica dos inibidores do ciclo celular p21 (nas linhagens GH3 e alfaT3.1) e p27 (nas linhagens GH3 e MMQ), com uma redução acentuada da expressão destes genes após retirada do cetoconazol do meio de cultura...

Ketoconazole, initially described as an antifungal agent, proved to be a potent inhibitor of steroidogenesis, allowing its use in the management of Cushing's disease as primary or after unsuccessfully surgery and waiting the effect of radiotherapy. During treatment with ketoconazole, there a reduction in the cortisol levels is observed, usually not accompanied by an elevation of plasmatic ACTH, as could be expected. This paradoxical phenomenon, characterized by reduced cortisol with ACTH levels inappropriately normal or not elevated, could be related to an additional action of ketoconazole on ACTH-producing pituitary cells. In agreement with this hypothesis, some in vitro studies in the 80's, evaluating ACTH secretion in the presence of ketoconazole, suggested its action in pituitary cells. In addition, ketoconazole activated apoptosis pathways in non-pituitary tumor cell lines. Therefore, the present study aims to revisit this topic and evaluate the in vitro effect of ketoconazole on cell viability and expression of genes involved in apoptosis and DNA replication by RT-qPCR in immortalized pituitary tumoral corticotroph (AtT-20), gonadotroph (alphaT3.1), mammosomatotroph (GH3), mammotroph (MMQ) cell line. As a result, there was a reduction in pituitary cell viability with ketoconazole, in a concentration-dependent manner, due to stimulation of the extrinsic and intrinsic pathway of apoptosis, with increased expression of cell death receptors (eg. Fas, TNFR) and/or caspases (eg. -2, -3, -6, -7, -9). These results were associated with an increased gene expression of the cell cycle inhibitors p21 (in GH3 and alphaT3.1 cell line), and also p27 (in GH3 and MMQ cell line), with a significant reduction in the expression of these genes after removal of ketoconazole in the media. In conclusion, the ketoconazole have the potential of reduce cell viability in pituitary tumoral lineages possibly due to a cytotoxic effect (by increasing...

Muestreo de senos petrosos inferiores en el diagnóstico de pacientes con síndrome de Cushing dependiente de hormona adrenocorticotrópica / Inferior petrosal sinus sampling in the diagnosis of patients with adrenocorticotropic hormone-dependent Cushing’s syndrome

Resumen: El síndrome de Cushing endógeno es una de las enfermedades más difíciles de estudiar, dado que sus diferentes etiologías requieren una cuidadosa valoración diagnóstica desde el punto de vista clínico, bioquímico y radiológico. Con frecuencia, las características clínicas se solapan con las de enfermedades comunes y algunos pacientes tienen una presentación atípica. Una vez se establece la sospecha clínica, las pruebas bioquímicas de tamizaje permiten definir si existe un estado de hipercor-tisolismo endógeno; en caso afirmativo, el estudio prosigue con pruebas de laboratorio que ayudan a localizar la causa de la hipercortisolemia. En este punto es fundamental determinar si se trata de un síndrome de Cushing dependiente o no dependiente de hormona adrenocorticotrópica (ACTH) y en caso que sea dependiente, diferenciar entre origen hipofisario y un origen ectópico de la enfermedad. Dicha situación se puede resolver mediante el cateterismo y muestreo de los senos petrosos inferiores, el cual es un procedimiento invasivo y sensible para el diagnóstico diferencial entre el tumor hipofisario y el tumor ectópico secretor de ACTH...

Abstract: Endogenous Cushing’s syndrome is one of the most difficult diseases to study. It has different etiologies and requires a careful clinical, biochemical, and radiological diagnosis. Often, its signs and symptoms overlap those of common diseases and some patients have atypical presentations. Once the clinical suspicion is established, screening biochemical tests allow identifying of endogenous hypercortisolism.After identification, it is necessary to use the appropriate diagnostic approach that helps to recognize the source of hypercortisolism. It then becomes imperative to differentiate between an adrenocorticotropic hormone (ACTH)-dependent or ACTH-independent Cushing’s syndrome. In the case of an ACTH-dependent Cushing’s syndrome, one must further distinguish between pituitary and ectopic etiology. This diagnostic challenge can be solved with inferior petrosal sinus sampling, an invasive but sensitive procedure used to discriminate between ACTH-producing pituitary or ectopic ACTH-producing tumors...

Características clínicas y epidemiológicas del síndrome de cushing. Medellín, 1986-2010 / Clinical and epidemiological features of cushing’s syndrome. Medellín, 1986-2010

Introducción: El síndrome de Cushing, aunque poco frecuente, se asocia a una morbimortalidad significativa.En nuestro medio, no se cuenta aún con estudios que reporten las características clínicas y epidemiológicas de esta entidad. Por esta razón, en este estudio se describen los datos recopilados durante 24 años en 30 pacientes con síndrome de Cushing en la ciudad de Medellín, Colombia. Métodos:Estudio descriptivo retrospectivo, donde se evaluó el diagnóstico, tratamiento y desenlaces de pacientes con síndrome de Cushing, atendidos entre mayo de 1986 y enero de 2010 en los servicios de Endocrinología de la Universidad de Antioquia, Hospital Universitario de San Vicente Fundación. Resultados:Se encontraron seis casos de síndrome de Cushing independiente de la hormona adrenocorticotropa (ACTH), cuatro de origen ectópico y 20 de origen hipofisario. En las pruebas bioquímicas, solo hubo diferencias significativas en la prueba de supresión con dosis altas de dexametasona en la enfermedadde Cushing.

Introduction: Although Cushing’s syndrome is an uncommon disease, it is associated with significant morbidity and mortality. Thus far, there are no reports of the clinical and epidemiological characteristicsof this entity in our country. Consequently, this study was conducted to analyze data collected over 24 years in 30 patients with Cushing’s syndrome in the city of Medellin, Colombia. Methods: A retrospective descriptive study was conducted to evaluate the diagnostic approach, treatment and outcomes of patients with Cushing’s syndrome between May, 1986 and January, 2010 in the Endocrinology Service at the University of Antioquia and in the Hospital Universitario San Vicente Fundación. Results: We found six cases of ACTH-independent Cushing’s syndrome, four ectopic tumors and 20 tumors of pituitaryorigin. Regarding biochemical tests, there was statistically significant difference in suppression test with high-dose dexamethasone in Cushing’s disease.

Comparisons between Macroadenomas and Microadenomas in Cushing's Disease: Characteristics of Hormone Secretion and Clinical Outcomes

It has been suggested that the patients with Cushing's disease secondary to pituitary macroadenomas (>10 mm) have higher basal adrenocorticotropic hormone (ACTH) levels, which are less suppressible on high-dose dexamethasone suppression tests (HDDST). We compared the clinical and biochemical characteristics of patients with macroadenomas (N=7) and microadenomas (N=23) who were diagnosed at Samsung Medical Center in Korea between 1996 and 2006. Basal morning plasma ACTH levels were 101.5+/-23.2 pg/mL for macroadenoma patients and 83.6+/-11.1 pg/mL for microadenoma patients (mean+/-SEMs) (p=0.44). Morning serum cortisol levels were 26.8+/-3.2 microgram/dL for macroadenoma patients and 29.5 +/-2.9 microgram/dL for microadenoma patients (p=0.77). The proportion of patients who showed suppressibility on HDDST was almost identical in the two groups (71.4% [5/7] for macroadenoma patients vs. 72.7% [16/22] for microadenoma patients, p=1.00). Furthermore, the remission rate with trans-sphenoidal surgery was similar between the two groups (100% [5/5] for macroadenoma patients vs. 73.3% [11/ 15] for microadenoma patients, p=0.53). Thus, tumor size is not a major determinant of hormone secretion or clinical outcomes in patients with Cushing's disease.